Apigenin, A Plant Flavone Playing Noble Roles in Cancer Prevention Via Modulation of Key Cell Signaling Networks

Deepti       Singh; Mohammad    A.   Khan; Hifzur    R.   Siddique
doi:10.2174/1574892814666191026095728
Abstract

Background: Cancer is a global health problem and the continuous rise in incidence and mortality due to cancer carries a real economic burden to all countries. Accumulation of genetic mutation, exposure of environmental carcinogens and food habits due to change in lifestyles are the key reasons for cancer. Targeting cancer cells, we need a multitargeting molecule with low/no toxicity.
Objective: To review the current update of the research status of chemopreventive/therapeutic molecule, Apigenin.
Methods: Compare the results of the published articles and granted patents on this compound. We also discuss the pros and cons of the present research and future direction.
Results: Cancer cells have characteristic alterations and dysregulation of various cell signaling pathways that control cell homeostasis, proliferation, motility, and survival in normal cells. Natural flavonoids are the compounds well known for their anti-inflammatory, anti-oxidant, and anti-cancerous properties. Apigenin, along with several other physiological effects, has a very low intrinsic toxicity and striking effects on the proliferation of cancer cells. Interestingly, this multitargeting molecule is getting wide acceptance among researchers. It is evident from the recent patents filed in this compound. At present, three patents have been granted only on the anticancer properties of apigenin.
Conclusion: This mini-review will explain the present research status of apigenin and will further shine some light on how apigenin performs its anti-cancerous actions by interfering with the key cellsignaling pathways.
Keywords: Apigenin, bioavailability, cancer, cell signaling, chemoresistance, patents, prevention, therapy.
« Previous Next »
[1] 
Mishra AP, Salehi B, Sharifi-Rad M, Pezzani R, Kobarfard F, Sharifi-Rad J, et al. Programmed cell death, from a cancer perspective: An overview. Mol Diagn Ther  2018; 22(3): 281-95.
[http://dx.doi.org/10.1007/s40291-018-0329-9] [PMID:  29560608] 
[2] 
Sankaranarayanan R, Ramadas K, Qiao YL. Managing the changing burden of cancer in Asia. BMC Med  2014; 12: 3.
[http://dx.doi.org/10.1186/1741-7015-12-3] [PMID:  24400922] 
[3] 
Blackadar CB. Historical review of the causes of cancer. World J Clin Oncol  2016; 7(1): 54-86.
[http://dx.doi.org/10.5306/wjco.v7.i1.54] [PMID:  26862491] 
[4] 
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell  2011; 144(5): 646-74.
[http://dx.doi.org/10.1016/j.cell.2011.02.013] [PMID:  21376230] 
[5] 
Siddique HR, Saleem M. Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: Preclinical and clinical evidences. Stem Cells  2012; 30(3): 372-8.
[http://dx.doi.org/10.1002/stem.1035] [PMID:  22252887] 
[6] 
Siddique HR, Feldman DE, Chen CL, Punj V, Tokumitsu H, Machida K. NUMB phosphorylation destabilizes p53 and promotes self-renewal of tumor-initiating cells by a NANOG-dependent mechanism in liver cancer. Hepatology  2015; 62(5): 1466-79.
[http://dx.doi.org/10.1002/hep.27987] [PMID:  26174965] 
[7] 
Arjmand F, Afsan Z, Sharma S, Parveen S, Yousuf I, Sartaj S, et al. Recent advances in metalodrug-like molecules targetting non-coding RNAs (ncRNAs) in cancer chemotherapy. Coord Chem Rev  2019; 387: 47-59.
[http://dx.doi.org/10.1016/j.ccr.2019.02.015] 
[8] 
Sever R, Brugge JS. Signal transduction in cancer. Cold Spring Harb Perspect Med  2015; 5(4)a006098
[http://dx.doi.org/10.1101/cshperspect.a006098] [PMID:  25833940] 
[9] 
Kumar S, Pandey AK. Chemistry and biological activities of Flavonoids: An overview. The Sci World J 2013 2013. Article ID162750
[http://dx.doi.org/10.1155/2013/162750] 
[10] 
Salehi B, Fokou PVT, Sharifi-Rad M, Zucca P, Pezzani R, Martins N, et al. The therapeutic potential of naringenin: A review of clinical trials. Pharmaceuticals (Basel)  2019; 12(1)E11
[http://dx.doi.org/10.3390/ph12010011] [PMID:  30634637] 
[11] 
Salehi B, Venditti A, Sharifi-Rad M, Kręgiel D, Sharifi-Rad J, Durazzo A, et al. The therapeutic potential of apigenin. Int J Mol Sci  2019; 20(6)E1305
[http://dx.doi.org/10.3390/ijms20061305] [PMID:  30875872] 
[12] 
Batra P, Sharma AK. Anti-cancer potential of flavonoids: Recent trends and future perspectives. 3 Biotech  2013; 3(6): 439-59.
[http://dx.doi.org/10.1007/s13205-013-0117-5] [PMID:  28324424] 
[13] 
Leopoidin M, Pitarch IP, Russo N, Toscano M. Structure, conformation, and electronic properties of apigenin, luteolin and taxifolin antioxidants. A First principle theoretical study. J Phys Chem A  2004; 108(1): 92-6.
[http://dx.doi.org/10.1021/jp035901j] 
[14] 
Gradolatto A, Basly JP, Berges R, Teyssier C, Chagnon MC, Siess MH, et al. Pharmacokinetics and metabolism of apigenin in female and male rats after a single oral administration. Drug Metab Dispos  2005; 33(1): 49-54.
[http://dx.doi.org/10.1124/dmd.104.000893] [PMID:  15466493] 
[15] 
Gupta S, Afaq F, Mukhtar H. Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem and Biophys Res Commun  2001; 287: 914-20.
[16] 
Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease, and cancer. Pharmacol Rev  2000; 52(4): 673-751.
[PMID:  11121513] 
[17] 
Singh P, Mishra SK, Noel S, Sharma S, Rath SK. Acute exposure of apigenin induces hepatotoxicity in Swiss mice. PLoS One  2012; 7(2)e31964
[http://dx.doi.org/10.1371/journal.pone.0031964] [PMID:  22359648] 
[18] 
Shukla S, Bhaskaran N, Babcook MA, Fu P, Maclennan GT, Gupta S. Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway. Carcinogenesis  2014; 35(2): 452-60.
[http://dx.doi.org/10.1093/carcin/bgt316] [PMID:  24067903] 
[19] 
Silvan S, Manoharan S, Baskaran N, Karthikeyan S, Prabhakar MM. Protective effect of apigenin on 7, 12-Dimethybenz(A) anthracene induced glycoconjugates in the plasma and buccal mucosa of golden Syrian hamsters. Int J Pharm Sci Res  2011; 1753-8.
[20] 
Tatsuta A, Iishi H, Baba M, Yano H, Murata K, Mukai M, et al. Suppression by apigenin of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in Wistar rats. Clin Exp Metastasis  2000; 18(8): 657-62.
[http://dx.doi.org/10.1023/A:1013133803806] [PMID:  11827069] 
[21] 
Zhong Y, Krisanapun C, Lee SH, Nualsanit T, Sams C, Peungvicha P, et al. Molecular targets of apigenin in colorectal cancer cells: Involvement of p21, NAG-1 and p53. Eur J Cancer  2010; 46(18): 3365-74.
[http://dx.doi.org/10.1016/j.ejca.2010.07.007] [PMID:  20709524] 
[22] 
Shukla S, Gupta S. Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft. Mol Cancer Ther  2006; 5(4): 843-52.
[http://dx.doi.org/10.1158/1535-7163.MCT-05-0370] [PMID:  16648554] 
[23] 
Budhraja A, Gao N, Zhang Z, Son YO, Cheng S, Wang X, et al. Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo. Mol Cancer Ther  2012; 11(1): 132-42.
[http://dx.doi.org/10.1158/1535-7163.MCT-11-0343] [PMID:  22084167] 
[24] 
Masuelli L, Benvenuto M, Mattera R, Di Stefano E, Zago E, Taffera G, et al. In vitro and in vivo anti-tumoral effects of the flavonoid apigenin in malignant mesothelioma. Front Pharmacol  2017; 8: 373.
[25] 
Seo HS, Jo JK, Ku JM, Choi HS, Choi YK, Woo JK, et al. Induction of caspase-dependent extrinsic apoptosis by apigenin through inhibition of signal transducer and activator of transcription 3 (STAT3) signalling in HER2-overexpressing BT-474 breast cancer cells. Biosci Rep  2015; 35(6) e00276
[http://dx.doi.org/10.1042/BSR20150165] [PMID:  26500281] 
[26] 
Zhu J, Cai Y, Xu K, Ren X, Sun J, Lu S, et al. Beclin1 overexpression suppresses tumor cell proliferation and survival via an autophagy-dependent pathway in human synovial sarcoma cells. Oncol Rep  2018; 40(4): 1927-36.
[http://dx.doi.org/10.3892/or.2018.6599] [PMID:  30066884] 
[27] 
Zeng X, Huang H, Tamai K, Zhang X, Harada Y, Yokota C, et al. Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development  2008; 135(2): 367-75.
[http://dx.doi.org/10.1242/dev.013540] [PMID:  18077588] 
[28] 
Lee Y, Sung B, Kang YJ, Kim DH, Jang JY, Hwang SY, et al. Apigenin-induced apoptosis is enhanced by inhibition of autophagy formation in HCT116 human colon cancer cells. Int J Oncol  2014; 44(5): 1599-606.
[http://dx.doi.org/10.3892/ijo.2014.2339] [PMID:  24626522] 
[29] 
Maggioni D, Garavello W, Rigolio R, Pignataro L, Gaini R, Nicolini G. Apigenin impairs oral squamous cell carcinoma growth in vitro inducing cell cycle arrest and apoptosis. Int J Oncol  2013; 43(5): 1675-82.
[http://dx.doi.org/10.3892/ijo.2013.2072] [PMID:  23969487] 
[30] 
Zhang L, Cheng X, Gao Y, Zheng J, Xu Q, Sun Y, et al. Apigenin induces autophagic cell death in human papillary thyroid carcinoma BCPAP cells. Food Funct  2015; 6(11): 3464-72.
[http://dx.doi.org/10.1039/C5FO00671F] [PMID:  26292725] 
[31] 
Pham H, Chen M, Takahashi H, King J, Reber HA, Hines OJ, et al. Apigenin inhibits NNK-induced focal adhesion kinase activation in pancreatic cancer cells. Pancreas  2012; 41(8): 1306-15.
[http://dx.doi.org/10.1097/MPA.0b013e31824d64d9] [PMID:  22889981] 
[32] 
Kim EY, Kim AK. Apigenin sensitizes Huh-7 human hepatocellular carcinoma cells to TRAIL-induced apoptosis. Biomol Ther (Seoul)  2012; 20(1): 62-7.
[http://dx.doi.org/10.4062/biomolther.2012.20.1.062] [PMID:  24116276] 
[33] 
D’Arcy MS. Cell death: A review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int  2019; 43(6): 582-92.
[http://dx.doi.org/10.1002/cbin.11137] [PMID:  30958602] 
[34] 
Shukla S, Fu P, Gupta S. Apigenin induces apoptosis by targeting inhibitor of apoptosis proteins and Ku70-Bax interaction in prostate cancer. Apoptosis  2014; 19(5): 883-94.
[http://dx.doi.org/10.1007/s10495-014-0971-6] [PMID:  24563225] 
[35] 
Wang IK, Lin-Shiau SY, Lin JK. Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells. Eur J Cancer  1999; 35(10): 1517-25.
[http://dx.doi.org/10.1016/S0959-8049(99)00168-9] [PMID:  10673981] 
[36] 
Abu-Yousif AO, Smith KA, Getsios S, Green KJ, Van Dross RT, Pelling JC. Enhancement of UVB-induced apoptosis by apigenin in human keratinocytes and organotypic keratinocyte cultures. Cancer Res  2008; 68(8): 3057-65.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-2763] [PMID:  18413777] 
[37] 
Gupta S, Afaq F, Mukhtar H. Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells. Oncogene  2002; 21(23): 3727-38.
[http://dx.doi.org/10.1038/sj.onc.1205474] [PMID:  12032841] 
[38] 
Baddani M. Autophagy mechanism, regulation, functions and disorder. ISRN Cell Biology (Basel)  2012; 2012 Article ID:927064
[http://dx.doi.org/10.5402/2012/927064] 
[39] 
Fulda S. Autophagy in cancer therapy. Front Oncol  2017; 7: 128.
[http://dx.doi.org/10.3389/fonc.2017.00128] [PMID:  28674677] 
[40] 
Gaballah HH, Gaber RA, Mohamed DA. Apigenin potentiates the antitumor activity of 5-FU on solid Ehrlich carcinoma: Crosstalk between apoptotic and JNK-mediated autophagic cell death platforms. Toxicol Appl Pharmacol  2017; 316: 27-35.
[http://dx.doi.org/10.1016/j.taap.2016.12.012] [PMID:  28025107] 
[41] 
Wang Q, Zeng P, Liu Y, Wen G, Fu X, Sun X. Inhibition of autophagy ameliorates atherogenic inflammation by augmenting apigenin-induced macrophage apoptosis. Int Immunopharmacol  2015; 27(1): 24-31.
[http://dx.doi.org/10.1016/j.intimp.2015.04.018] [PMID:  25899084] 
[42] 
Ruela-de-Sousa RR, Fuhler GM, Blom N, Ferreira CV, Aoyama H, Peppelenbosch MP. Cytotoxicity of apigenin on leukemia cell lines: Implications for prevention and therapy. Cell Death Dis  2010; 1(1) e19
[http://dx.doi.org/10.1038/cddis.2009.18] [PMID:  21364620] 
[43] 
Tong X, Smith KA, Pelling JC. Apigenin, a chemopreventive bioflavonoid, induces AMP-activated protein kinase activation in human keratinocytes. Mol Carcinog  2012; 51(3): 268-79.
[http://dx.doi.org/10.1002/mc.20793] [PMID:  21538580] 
[44] 
Cao X, Liu B, Cao W, Zhang W, Zhang F, Zhao H, et al. Autophagy inhibition enhances apigenin-induced apoptosis in human breast cancer cells. Chin J Cancer Res  2013; 25(2): 212-22.
[PMID:  23592903] 
[45] 
Yang J, Pi C, Wang G. Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells. Biomed Pharmacother  2018; 103: 699-707.
[46] 
Coelho PL, Oliveira MN, da Silva AB, Pitanga BP, Silva VD, Faria GP, et al. The flavonoid apigenin from Croton betulaster Mull inhibits proliferation, induces differentiation and regulates the inflammatory profile of glioma cells. Anticancer Drugs  2016; 27(10): 960-9.
[http://dx.doi.org/10.1097/CAD.0000000000000413] [PMID:  27622606] 
[47] 
Zhu Y, Wu J, Li S, Wang X, Liang Z, Xu X, et al. Apigenin inhibits migration and invasion via modulation of epithelial mesenchymal transition in prostate cancer. Mol Med Rep  2015; 11(2): 1004-8.
[http://dx.doi.org/10.3892/mmr.2014.2801] [PMID:  25351792] 
[48] 
Hu XW, Meng D, Fang J. Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal adhesion kinase. Carcinogenesis  2008; 29(12): 2369-76.
[http://dx.doi.org/10.1093/carcin/bgn244] [PMID:  18974065] 
[49] 
Chunhua L, Donglan L, Xiuqiong F, Lihua Z, Qin F, Yawei L, et al. Apigenin up-regulates transgelin and inhibits invasion and migration of colorectal cancer through decreased phosphorylation of AKT. J Nutr Biochem  2013; 24(10): 1766-75.
[http://dx.doi.org/10.1016/j.jnutbio.2013.03.006] [PMID:  23773626] 
[50] 
Zhao G, Han X, Cheng W, Ni J, Zhang Y, Lin J, et al. Apigenin inhibits proliferation and invasion, and induces apoptosis and cell cycle arrest in human melanoma cells. Oncol Rep  2017; 37(4): 2277-85.
[http://dx.doi.org/10.3892/or.2017.5450] [PMID:  28260058] 
[51] 
Dai J, Van Wie PG, Fai LY, Kim D, Wang L, Poyil P, et al. Downregulation of NEDD9 by apigenin suppresses migration, invasion, and metastasis of colorectal cancer cells. Toxicol Appl Pharmacol  2016; 311: 106-12.
[http://dx.doi.org/10.1016/j.taap.2016.09.016] [PMID:  27664007] 
[52] 
Cantley LC. The phosphoinositide 3-kinase pathway. Science  2002; 296(5573): 1655-7.
[http://dx.doi.org/10.1126/science.296.5573.1655] [PMID:  12040186] 
[53] 
Cheung M, Testa JR. Diverse mechanisms of AKT pathway activation in human malignancy. Curr Cancer Drug Targets  2013; 13(3): 234-44.
[http://dx.doi.org/10.2174/1568009611313030002] [PMID:  23297823] 
[54] 
Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D. PI3K and mTOR signaling pathways in cancer: New data on targeted therapies. Curr Oncol Rep  2012; 14(2): 129-38.
[http://dx.doi.org/10.1007/s11912-012-0227-y] [PMID:  22350330] 
[55] 
Tong X, Pelling JC. Targeting the PI3K/Akt/mTOR axis by apigenin for cancer prevention. Anticancer Agents Med Chem  2013; 13(7): 971-8.
[http://dx.doi.org/10.2174/18715206113139990119] [PMID:  23272913] 
[56] 
Kaur P, Shukla S, Gupta S. Plant flavonoid apigenin inactivates Akt to trigger apoptosis in human prostate cancer: An in vitro and in vivo study. Carcinogenesis  2008; 29(11): 2210-7.
[http://dx.doi.org/10.1093/carcin/bgn201] [PMID:  18725386] 
[57] 
Yan X, Qi M, Li P, Zhan Y, Shao H. Apigenin in cancer therapy: Anti-cancer effects and mechanisms of action. Cell Biosci  2017; 7: 50.
[http://dx.doi.org/10.1186/s13578-017-0179-x] [PMID:  29034071] 
[58] 
Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell  2003; 115(5): 577-90.
[http://dx.doi.org/10.1016/S0092-8674(03)00929-2] [PMID:  14651849] 
[59] 
Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, et al. AMPK phosphorylation of Raptor mediates a metabolic checkpoint. Mol Cell  2008; 30(2): 214-26.
[http://dx.doi.org/10.1016/j.molcel.2008.03.003] [PMID:  18439900] 
[60] 
Constantinescu SN, Girardot M, Pecquet C. Mining for JAK-STAT mutations in cancer. Trends Biochem Sci  2008; 33(3): 122-31.
[http://dx.doi.org/10.1016/j.tibs.2007.12.002] [PMID:  18291658] 
[61] 
Schwaller J. Modeling ETV6-JAK2-induced leukemia: Insights from the zebrafish. Haematologica  2012; 97(12): 1783-5.
[http://dx.doi.org/10.3324/haematol.2012.080754] [PMID:  23204479] 
[62] 
Warsch W, Walz C, Sexl V. JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia. Blood  2013; 122(13): 2167-75.
[http://dx.doi.org/10.1182/blood-2013-02-485573] [PMID:  23926299] 
[63] 
Morales JK, Falanga YT, Depcrynski A, Fernando J, Ryan JJ. Mast cell homeostasis and the JAK-STAT pathway. Genes Immun  2010; 11(8): 599-608.
[http://dx.doi.org/10.1038/gene.2010.35] [PMID:  20535135] 
[64] 
Villarino AV, Kanno Y, Ferdinand JR, O’Shea JJ. Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol  2015; 194(1): 21-7.
[http://dx.doi.org/10.4049/jimmunol.1401867] [PMID:  25527793] 
[65] 
Cao HH, Chu JH, Kwan HY, Su T, Yu H, Cheng CY, et al. Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma. Sci Rep  2016; 6: 21731.
[http://dx.doi.org/10.1038/srep21731] [PMID:  26911838] 
[66] 
Seo HS, Ku JM, Choi HS, Woo JK, Jang BH, Go H, et al. Apigenin induces caspase-dependent apoptosis by inhibiting signal transducer and activator of transcription 3 signaling in HER2-overexpressing SKBR3 breast cancer cells. Mol Med Rep  2015; 12(2): 2977-84.
[http://dx.doi.org/10.3892/mmr.2015.3698] [PMID:  25936427] 
[67] 
Suh YA, Jo SY, Lee HY, Lee C. Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells. Int J Oncol  2015; 46(3): 1405-11.
[http://dx.doi.org/10.3892/ijo.2014.2808] [PMID:  25544427] 
[68] 
Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis  2008; 4(2): 68-75.
[http://dx.doi.org/10.4161/org.4.2.5851] [PMID:  19279717] 
[69] 
Abrahamsson AE, Geron I, Gotlib J, Dao KH, Barroga C1F, Newton IG, et al. Glycogen synthase kinase 3β missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci USA  2009; 106(10): 3925-9.
[http://dx.doi.org/10.1073/pnas.0900189106] [PMID:  19237556] 
[70] 
Lammi L, Arte S, Somer M, Jarvinen H, Lahermo P, Thesleff I, et al. Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet  2004; 74(5): 1043-50.
[http://dx.doi.org/10.1086/386293] [PMID:  15042511] 
[71] 
Galy O, Chemin I, Le Roux E, Villar S, Le Calvez-Kelm F, Lereau M, et al. Mutations in TP53 and CTNNB1 in relation to hepatitis B and C infections in hepatocellular carcinomas from Thailand. Hepat Res Treat  2011; 2011697162
[http://dx.doi.org/10.1155/2011/697162] [PMID:  21760996] 
[72] 
Björklund P, Akerström G, Westin G. An LRP5 receptor with internal deletion in hyperparathyroid tumors with implications for deregulated WNT/beta-catenin signaling. PLoS Med  2007; 4(11) e328
[http://dx.doi.org/10.1371/journal.pmed.0040328] [PMID:  18044981] 
[73] 
Oikonomou E, Barreto DC, Soares B, De Marco L, Buchfelder M, Adams EF. Beta-catenin mutations in craniopharyngiomas and pituitary adenomas. J Neurooncol  2005; 73(3): 205-9.
[http://dx.doi.org/10.1007/s11060-004-5232-z] [PMID:  15980970] 
[74] 
Novellasdemunt L, Antas P, Li VS. Targeting Wnt signaling in colorectal cancer. A review in the theme: Cell signalling: Proteins, pathways, mechanisms. Am J Physiol Cell Physiol  2015; 309(8): C511-21.
[http://dx.doi.org/10.1152/ajpcell.00117.2015] [PMID:  26289750] 
[75] 
Lin CM, Chen HH, Lin CA, Wu HC, Sheu JJ, Chen HJ. Apigenin-induced lysosomal degradation of β-catenin in Wnt/β-catenin signaling. Sci Rep  2017; 7(1): 372.
[http://dx.doi.org/10.1038/s41598-017-00409-z] [PMID:  28337019] 
[76] 
Xu M, Wang S, Song YU, Yao J, Huang K, Zhu X. Apigenin suppresses colorectal cancer cell proliferation, migration and invasion via inhibition of the Wnt/β-catenin signaling pathway. Oncol Lett  2016; 11(5): 3075-80.
[http://dx.doi.org/10.3892/ol.2016.4331] [PMID:  27123066] 
[77] 
Shukla S, MacLennan GT, Flask CA, Fu P, Mishra A, Resnick MI, et al. Blockade of β-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. Cancer Res  2007; 67(14): 6925-35.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-0717] [PMID:  17638904] 
[78] 
Keshet Y, Seger R. The MAP kinase signaling cascades: A system of hundreds of components regulates a diverse array of physiological functions. Methods Mol Biol  2010; 661: 3-38.
[http://dx.doi.org/10.1007/978-1-60761-795-2_1] [PMID:  20811974] 
[79] 
Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res  2002; 12(1): 9-18.
[http://dx.doi.org/10.1038/sj.cr.7290105] [PMID:  11942415] 
[80] 
Yang S, Liu G. Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. Oncol Lett  2017; 13(3): 1041-7.
[http://dx.doi.org/10.3892/ol.2017.5557] [PMID:  28454211] 
[81] 
De Luca A, Maiello MR, D’Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets  2012; 16(16)(Suppl. 2): S17-27.
[http://dx.doi.org/10.1517/14728222.2011.639361] [PMID:  22443084] 
[82] 
Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene  2007; 26(22): 3279-90.
[http://dx.doi.org/10.1038/sj.onc.1210421] [PMID:  17496922] 
[83] 
Chen M, Wang X, Zha D, Cai F, Zhang W, He Y, et al. Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner. Sci Rep  2016; 6: 35468.
[http://dx.doi.org/10.1038/srep35468] [PMID:  27752089] 
[84] 
Shao H, Jing K, Mahmoud E, Huang H, Fang X, Yu C. Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263. Mol Cancer Ther  2013; 12(12): 2640-50.
[http://dx.doi.org/10.1158/1535-7163.MCT-13-0066] [PMID:  24126433] 
[85] 
Shukla S, MacLennan GT, Fu P, Gupta S. Apigenin attenuates insulin-like growth factor-I signaling in an autochthonous mouse prostate cancer model. Pharm Res  2012; 29(6): 1506-17.
[http://dx.doi.org/10.1007/s11095-011-0625-0] [PMID:  22139534] 
[86] 
Hasnat MA, Pervin M, Lim JH, Lim BO. Apigenin attenuates melanoma cell migration by inducing anoikis through integrin and focal adhesion kinase inhibition. Molecules  2015; 20(12): 21157-66.
[http://dx.doi.org/10.3390/molecules201219752] [PMID:  26633318] 
[87] 
Shukla S, Gupta S. Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle  2007; 6(9): 1102-14.
[http://dx.doi.org/10.4161/cc.6.9.4146] [PMID:  17457054] 
[88] 
Lim W, Park S, Bazer FW, Song G. Apigenin reduces survival of choriocarcinoma cells by inducing apoptosis via the PI3K/AKT and ERK1/2 MAPK pathways. J Cell Physiol  2016; 231(12): 2690-9.
[http://dx.doi.org/10.1002/jcp.25372] [PMID:  26970256] 
[89] 
Gutierrez-Uribe JA, Serna-Saldivar SRO, Moreno-Cuevas JE, Hernandez-Brenes C, Guajardo-Touche EM. Cancer cell
growth inhibition by black bean (Phaseolus vulgaris L) extracts US7763292. (2010).
[90] 
Uckun FM. EGF-Genistein conjugates for the treatment of cancer US5911995. (1999).
[91] 
Wen-zhe MA. Use of nobiletin in cancer treatment US9808477. (2017).
[92] 
Young C. Methods and compositions for inhibiting the proliferation
of prostate cancer cells US6680342. (2004).
[93] 
Walle T. A method of treating colon cancer by administering apigenin,
luteolin, diosmetin and chrysin WO2001058410. (2001).
[94] 
Liu Y. A kind of chrysin phenylalanine derivative with anti-lung
cancer activity CN109824642. (2019).
[95] 
Mukhtar H, Khan N, Mohammad A, Afaq F. Methods of treating
androgen dependent prostate cancer by administering an active
pharmaceutical ingredient being fisetin, 3,3',4',7-tetrahydroxyflavone
or a derivative thereof, in an oral, transdermal or topical
dosage form US20100010078. (2010).
[96] 
Young SS. Use in anti-cancer agent of 4'-o-glucose-luteolin KR20100134966. (2010).
[97] 
Nakajima N, Kawashima N. Cancer proliferation inhibitor JP2012025724. (2012).
[98] 
Vorsa N, Vvedenskaya IO, Huang M-T, Rosen LRSL. Antiinflammatory
cranberry flavonol extract preparations US7270837. (2007).
[99] 
Zakaryan H, Arabyan E, Oo A, Zandi K. Flavonoids: Promising natural compounds against viral infections. Arch Virol  2017; 162(9): 2539-51.
[http://dx.doi.org/10.1007/s00705-017-3417-y] [PMID:  28547385] 
[100] 
Yuen K. Baicalin and its derivatives as a treatment for SARS
corona virus infection or other related infections WO2005044291. (2005).
[101] 
Hwa-Jeong C. Flavonoid comprising anti-virus activity KR101334348. (2013).
[102] 
Kim JW, Han JJ, Park EY, et al. Genistein derivatives and anti-fungal composition
containing the same WO2007061254. (2007).
[103] 
Yuan J. Application of kaempferol as synergist of anti-fungal
medicaments CN102218052. (2012).
[104] 
Kim C. Pharmaceutical compositions for preventing or treating
lung cancer comprising apigenin, curcumin, and honokiol as active
ingredients KR101803000. (2017).
[105] 
Yang C. Applications of apigenin for preparation of medicines
inhibiting liver cancer epithelial-mesenchymal transition CN106377522. (2017).
[106] 
Kim BB. Method for improving anti-cancer effect of apigenin by
irradiation and pharmaceutical composition for treating or preventing
cancer comprising irradiated apigenin KR20160132185. (2016).
[107] 
Song KH. Pharmaceutical composition for preventing or treating
choriocarcinoma comprising apigenin, chrysophanol or mixture
thereof KR20180132212. (2018).
[108] 
Jiang BH. Apigenin for chemoprevention, and chemotherapy
combined with therapeutic reagents US8377918. (2013).
[109] 
Liu Y. Safe natural pharmaceutical composition for treating cancer US20040072790. (2004).
[110] 
Cohen I. Methods and compositions for the treatment of cancer AU2009289644. (2010).
[111] 
Lei Z. Pharmaceutical composition having apigenin and apigenin
derivative as well as histone deacetylase inhibitors and application
thereof CN102441167. (2014).
[112] 
He B, You L, Xu Z, Jablons DM. Methods for treating cancer
by inhibiting Wnt signaling US20090304695. (2009).
[113] 
Hollman PC, Katan MB. Health effects and bioavailability of dietary flavonols. Free Radic Res  1999; 31: S75-80.
[http://dx.doi.org/10.1080/10715769900301351] [PMID:  10694044] 
[114] 
Ross JA, Kasum CM. Dietary flavonoids: Bioavailability, metabolic effects, and safety. Annu Rev Nutr  2002; 22: 19-34.
[http://dx.doi.org/10.1146/annurev.nutr.22.111401.144957] [PMID:  12055336] 
[115] 
Walle UK, Walle T. Induction of human UDP-glucuronosyltransferase UGT1A1 by flavonoids-structural requirements. Drug Metab Dispos  2002; 30(5): 564-9.
[http://dx.doi.org/10.1124/dmd.30.5.564] [PMID:  11950788] 
[116] 
Ding B, Chen H, Wang C, Zhai Y, Zhai G. Preparation and in vitro evaluation of apigenin loaded lipid nanocapsules. J Nanosci Nanotechnol  2013; 13(10): 6546-52.
[http://dx.doi.org/10.1166/jnn.2013.7763] [PMID:  24245113] 
[117] 
Cochran DB, Gray LN, Anderson KW, Dziubla TD. Degradable poly(apigenin) polymer inhibits tumor cell adhesion to vascular endothelial cells. J Biomed Mater Res B Appl Biomater  2016; 104(7): 1438-47.
[http://dx.doi.org/10.1002/jbm.b.33486] [PMID:  26251070] 
[118] 
Rajendran I, Dhandapani H, Anantharaman R, Rajaram R. Apigenin mediated gold nanoparticle synthesis and their anti-cancer effect on human epidermoid carcinoma (A431) cells. RSC Advances  2015; 5: 51055-66.
[http://dx.doi.org/10.1039/C5RA04303D] 
Rights & Permissions Print Cite
Article Metrics
35
3
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1574892814666191026095728	Print ISSN 1574-8928
Publisher Name Bentham Science Publisher	Online ISSN 2212-3970
Recent Patents on Anti-Cancer Drug Discovery

Apigenin, A Plant Flavone Playing Noble Roles in Cancer Prevention Via Modulation of Key Cell Signaling Networks

Abstract

Related Journals

Related Books

Related Articles
